摘要
To the Editor:Hepatocellular carcinoma(HCC)is the third most lethal malignancy globally.[1]Besides sorafenib,lenvatinib is currently the second approved targeted agent for the first-line treatment of HCC in 2018.Lenvatinib is an oral multikinase inhibitor that targets vascular endothelial growth factor(VEGF)receptors 1 to 3,fibroblast growth factor receptors 1 to 4,platelet-derived growth factor receptor a,RET,and KIT.[2]Patients who received lenvatinib experienced diarrhoea,and alope and more instances of hypertension,proteinuria,and hypothyroidism.Here,we report two patients that developed irreversible pancreatic atrophy as a novel adverse event of lenvatinib.
基金
This work was supported by a grant from the Big Data Research and Development Project of the General Hospital of People's Liberation Army(No.2018MBD-011).
